<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4837">
  <stage>Registered</stage>
  <submitdate>9/12/2014</submitdate>
  <approvaldate>9/12/2014</approvaldate>
  <nctid>NCT02315144</nctid>
  <trial_identification>
    <studytitle>An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients</studytitle>
    <scientifictitle>A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TV48108-COPD-10045</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TV48108
Treatment: drugs - Placebo

Experimental: TV48108 - Healthy Volunteers - Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg

Placebo Comparator: Placebo - Healthy Volunteers - Placebo

Experimental: TV48108 15 µg COPD - Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.

Experimental: TV48108 60 µg COPD - Stage 2

Experimental: TV48108 120 µg COPD - Stage 2 .


Treatment: drugs: TV48108
TV48108 15, 60, 120 µg

Treatment: drugs: Placebo
Placebo Comparator

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours (FEV1 AUC0-12h).</outcome>
      <timepoint>Day 1 (pre-dose, up to 12 hours post-dose)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Baseline Adjusted Trough 12 hour forced expiratory volume in 1 second (FEV1)</outcome>
      <timepoint>Day 1 (pre-dose, up to 12 hours post-dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Adverse Events</outcome>
      <timepoint>28 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stage 1 (Healthy Volunteers)

          -  Male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass
             index (BMI) of less than 30 kg/m^2.

          -  In good health as determined by medical and psychiatric history, physical examination,
             electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology.

          -  Other criteria apply, please contact the investigator for more information

        Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

          -  Male or female; 40 to 75 years of age, inclusive with a minimum body weight of 40 kg

          -  Current or former cigarette smokers with a history of cigarette smoking of =10 pack
             years at the screening visit

          -  Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung
             Disease guidelines.

          -  Other criteria apply, please contact the investigator for more information</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Stage 1 (Healthy Volunteers)

          -  History or current evidence of a clinically significant or uncontrolled disease

          -  Any disorder that may interfere with the absorption, distribution, metabolism or
             excretion of study drugs.

          -  History of severe allergy to milk protein

          -  Active smokers or former smokers who quit within 3 months of the first dose of study
             drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack
             per day for five years) are also excluded.

          -  Other criteria apply, please contact the investigator for more information

        Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

          -  Recent history of hospitalization due to an exacerbation of airway disease within 3
             months

          -  Need for increased treatments of COPD within 6 weeks prior to the screening visit

          -  History of and/or current diagnosis of asthma

          -  Known a1 antitrypsin deficiency, active lung infections (such as tuberculosis or
             pneumonia), and lung cancer are absolute exclusionary conditions

          -  Other criteria apply, please contact the investigator for more information</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>61</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Teva Investigational Site 78992 - Clayton</hospital>
    <hospital>Teva Investigational Site 78993 - Daws Park</hospital>
    <hospital>Teva Investigational Site 78991 - Melbourne</hospital>
    <postcode> - Clayton</postcode>
    <postcode> - Daws Park</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Teva Branded Pharmaceutical Products, R&amp;D Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to characterize the safety profile and duration of
      bronchodilation of a single dose of inhaled TV48108.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02315144</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Teva Medical Expert, MD</name>
      <address>TEVA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>